New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
09:10 EDTZLC, SM, MFRM, UCTT, SUNE, SCTY, DVN, GRMN, CG, ACT, CHTP, TS, X, SIG, OCROn The Fly: Pre-market Movers
UP AFTER EARNINGS: Garmin (GRMN), up 12%... Carlyle Group (CG), up 6.5%... Ultra Clean (UCTT), up 18%... SunEdison (SUNE), up 3%. ALSO HIGHER: Zales (ZLC), up 40% after Signet Jewelers (SIG) to acquire the company for $21.00 per share cash. Signet Jewelers is up 11.6% after the news... Chelsea Therapeutics (CHTP), up 33.5% after Northera granted FDA accelerated approval... Actavis (ACT), up 1.4% after reiterating standalone FY14 adjusted EPS view, shares upgraded at Goldman... Devon Energy (DVN), up 1.8% after earnings, announcing sale of Canadian conventional assets to Canadian Natural Resources (CNQ). DOWN AFTER EARNINGS: Mattress Firm (MFRM), down 10%... Omnicare (OCR), down 4.3%. ALSO LOWER: U.S. Steel (X), down 4.4%, Tenaris down 5.4% after U.S. excludes South Korea from steel tubing tariffs... SolarCity (SCTY), down 1.4% following downgrade at RW Baird... SM Energy (SM), down 11% after earnings, downgrades at Tudor Pickering and KeyBanc.
News For ZLC;SIG;X;TS;CHTP;ACT;CG;GRMN;DVN;SCTY;SUNE;UCTT;MFRM;SM;OCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 16, 2014
08:08 EDTACTActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
08:02 EDTACTIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
07:37 EDTSUNESunEdison enters into PV project Joint Venture with JIC Capital
SunEdison has entered into a joint venture agreement with JIC Capital to facilitate nonrecourse financing and develop, construct and own up to 1 GW of utility-scale solar photovoltaic projects in China over the next 3 years.
October 15, 2014
14:41 EDTXMissouri AG Chris Koster announces $266K settlement with U.S. Steel
Subscribe for More Information
11:46 EDTSUNEOptions with increasing implied volatility
Subscribe for More Information
08:23 EDTSCTYSolarCity offers Solar Bonds to investors
Subscribe for More Information
08:07 EDTSCTYSolarCity files automatic mixed securities shelf
Subscribe for More Information
07:40 EDTSUNESunEdison's Global Services Division surpasses 3 gigawatts of solar capacity
Subscribe for More Information
07:00 EDTTSTenaris initiated with a Hold at ISI Group
Subscribe for More Information
October 14, 2014
12:55 EDTSIGSignet Jewelers pullback a buying opportunity, says Stephens
Subscribe for More Information
10:01 EDTSMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AU Optronics (AUO) upgraded to Neutral from Sell at UBS... Antero Resources (AR) upgraded to Buy from Accumulate at KLR Group... BHP Billiton (BHP) upgraded to Neutral from Underperform at Credit Suisse... Bill Barrett (BBG) upgraded to Buy from Accumulate at KLR Group... BorgWarner (BWA) upgraded to Buy from Neutral at Goldman... CRH Plc. (CRH) upgraded to Buy from Neutral at Citigroup... Comstock Resources (CRK) upgraded to Buy from Accumulate at KLR Group... Cracker Barrel (CBRL) upgraded at Argus... Delphi Automotive (DLPH) upgraded to Buy from Neutral at Goldman... EOG Resources (EOG) upgraded at Bernstein... Eaton (ETN) upgraded to Overweight from Equal Weight at Barclays... Energizer (ENR) upgraded to Outperform from Market Perform at Wells Fargo... Energy Transfer Equity (ETE) upgraded to Outperform at RW Baird... Federal-Mogul (FDML) upgraded to Neutral from Sell at Goldman... Ford (F) upgraded to Neutral from Underperform at Buckingham... Gulfport Energy (GPOR) upgraded to Accumulate from Hold at KLR Group... Halcon Resources (HK) upgraded to Buy from Hold at KLR Group... HeartWare (HTWR) upgraded to Overweight from Neutral at Piper Jaffray... Helmerich & Payne (HP) upgraded to Outperform at FBR Capital... Legg Mason (LM) upgraded to Neutral from Underperform at BofA/Merrill... Level 3 (LVLT) upgraded to Buy from Hold at Gabelli... Magnum Hunter (MHR) upgraded to Buy from Hold at KLR Group... NetScout (NTCT) upgraded at DA Davidson... Netflix (NFLX) upgraded to Buy with $600 target at BTIG... Newfield Exploration (NFX) upgraded to Buy from Hold at KLR Group... Nielsen (NLSN) upgraded at Bernstein... Orbitz (OWW) upgraded to Outperform from Market Perform at FBR Capital... PDC Energy (PDCE) upgraded to Buy from Hold at KLR Group... Rackspace (RAX) upgraded to Buy from Hold at Evercore... Range Resources (RRC) upgraded to Accumulate from Hold at KLR Group... Rex Energy (REXX) upgraded to Buy from Accumulate at KLR Group... SM Energy (SM) upgraded to Buy from Accumulate at KLR Group... Sanchez Energy (SN) upgraded to Buy from Accumulate at KLR Group... Targa Resources (TRGP) upgraded to Buy from Accumulate at Tudor Pickering... Unilife (UNIS) upgraded to Buy from Neutral at Ladenburg... Universal Forest (UFPI) upgraded at Sterne Agee.
08:40 EDTSMSM Energy upgraded to Buy from Accumulate at KLR Group
Subscribe for More Information
08:04 EDTSIGSignet Jewelers reaffirms Q2 guidance
Subscribe for More Information
08:03 EDTSIGSignet Jewelers CEO Barnes resigns effective October 31, COO Light to succeed
Subscribe for More Information
07:46 EDTACTActavis should be able to mitigate Irish tax downside, says Leerink
Subscribe for More Information
07:37 EDTSUNESunEdison announces zero white space solar module technology
Subscribe for More Information
06:03 EDTACTMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
15:12 EDTACTActavis may see modest negative impact from Irish tax change, says BMO Capital
Subscribe for More Information
10:58 EDTSCTYSolarCity volatility elevated on wide price movement
Subscribe for More Information
08:03 EDTSCTYSolarCity lowered pricing in California, says JPMorgan
JPMorgan says SolarCity lowered its pricing in California, implementing a fixed price of 15c per watt, down from a prior average of 17c. To reflect the change, SolarCity dropped the NPV of its average new residential deployment to $1.75 per watt from $2.19 historically, the firm notes. JPMorgan cut its Retained Value estimates and dropped its price target for SolarCity shares to $74 from $83. The firm believes the price change could be tied to the proposed compression of rate tiers in 2015, allowing the company to address a larger market. It keeps an Overweight rating on SolarCity.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use